Hu D, Hu Y, Lei S, Wu D, et al. MET tyrosine kinase inhibitors in combination with EGFR tyrosine kinase inhibitors in NSCLC patients with EGFR mutations and acquired MET alterations: a systematic review and meta-analysis. BMC Cancer 2025;25:732.
PMID: 40251527